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Abstract The peroxisome proliferator-activated receptor
gamma (PPARc) is a ligand-activated transcriptional factor
that belongs to the nuclear hormone receptor superfamily.
PPARc was initially identified through its role in the reg-
ulation of glucose and lipid metabolism and cell differen-
tiation. It also influences the expression or activity of a
number of genes in a variety of signalling networks. These
include regulation of redox balance, fatty acid oxidation,
immune responses and mitochondrial function. Recent
studies suggest that the PPARc agonists may serve as good
candidates for the treatment of several neurodegenerative
disorders including Parkinson’s disease (PD), Alzheimer’s
disease, Huntington’s disease and amyotrophic lateral
sclerosis, even though multiple etiological factors con-
tribute to the development of these disorders. Recent
reports have also signposted a role for PPARc coactivator-
1a (PGC-1a) in several neurodegenerative disorders
including PD. In this review, we explore the current
knowledge of mechanisms underlying the beneficial effects
of PPARc agonists and PGC-1a in models of PD.




PPARs Peroxisome proliferator-activated receptors
TZDs Thiazolidinediones
PGC-1a Peroxisome proliferator-activated receptor
gamma coactivator-1 alpha
ROS Reactive oxygen species
SOD Superoxide dismutase
NQO1 NAD(P)H:quinone oxidoreductase 1
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
TFAM Mitochondrial transcription factor A
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MPP? 1-Methyl-4-phenylpyridinium ion
CNS Central nervous system
HO-1 Heme oxygenase-1




The peroxisome proliferator-activated receptors (PPARs)
are ligand-inducible transcription factors that belong to the
hormone nuclear receptor superfamily. They are involved
in the transcriptional control of genes regulating various
physiological processes such as lipid homeostasis, glucose
metabolism, inflammation, cellular differentiation and
proliferation [1, 2]. PPARs act mainly as lipid sensors,
regulating metabolism in response to dietary lipid intake
and direct the subsequent metabolism and storage of lipids
[3]. Three isoforms have been identified, PPARa, PPARb/
d, and PPARc. These three isoforms differ in terms of their
tissue distribution, ligand specificity and physiological
role. PPARa acts primarily to regulate energy homeostasis
through its ability to stimulate the breakdown of fatty acids
and cholesterol, driving gluconeogenesis and reduced
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triglyceride levels. This receptor in particular acts as a lipid
sensor, binding fatty acids and initiating their subsequent
metabolism. The PPARb/d receptors bind and respond to
VLDL-derived fatty acids, eicosanoids, including prosta-
glandin A1, and are involved in fatty acid oxidation.
PPARc stimulates adipocyte differentiation and lipid
metabolism. PPARc operates in the metabolism of lipid
and carbohydrate metabolism and its activation is related to
reduction of glucose levels [4].
Peroxisome proliferator-activated receptors (PPARs) are
activated by small, lipophilic compounds and regulate gene
expression by forming heterodimers with retinoid-X-
receptors. Once activated the PPAR/retinoid-X-receptors
heterodimer binds to the specific DNA sequence [peroxi-
some proliferator response element (PPRE)] on the pro-
moter region of PPAR target genes [2, 5] to modulate
transcriptional activity. The activity of PPARs is also
regulated by posttranslational modification such as phos-
phorylation and sumoylation [6, 7]. For example, there are
several mechanisms involved in PPARc inactivation. Thus,
phosphorylation can negatively or positively affect PPARc
activity depending on which specific protein residue is
modified [8–11]. The PPARc activity is decreased via the
ubiquitination degradation pathway [12]. Alternatively,
PPARc sumoylation promotes the repression of inflam-
matory or adipocyte differentiation genes [6, 13].
Peroxisome proliferator-activated receptor alpha
(PPARa) ligands include fibrates that are commonly used
for the treatment of hypertriglyceridemia and WY14,643
and GW7647. PPARb/d ligands include the prostacyclin
PGI2, and synthetic compounds GW0742, GW501516, and
GW7842. All PPARs can be activated by polyunsaturated
fatty acids with different affinities [14, 15]. Naturally
occurring PPARc ligands include long chain fatty acids,
other natural lipid ligands, eicosanoids and the prosta-
glandin 15d-PGJ2, but also few nonsteroidal antiinflam-
matory drugs, as ibuprofen, fenoprofen, and indomethacin
A [15–17]. Synthetic thiazolidinediones (TZDs), including
pioglitazone and rosiglitazone were originally designed as
PPARc agonists and are currently in clinical use as insulin-
sensitizing agents for the treatment of type 2 diabetes [15,
18].
Distribution of PPARs
Peroxisome proliferator-activated receptor alpha (PPARa)
is highly expressed in metabolically active tissues, such as
liver, kidney, intestine, heart, skeletal muscle, adrenal
gland and pancreas during foetal development of rodents
[19, 20]. In adult rodent organs, the distribution of PPARa
is similar to its foetal pattern of expression. In the central
nervous system (CNS), PPARa is expressed at very low
levels predominantly in astrocytes and PPARa is most
highly expressed in tissues that catabolise fatty acids, such
as the adult liver, heart, kidney, large intestine and skeletal
muscle [21]. PPARb/d is the most abundant in the CNS,
PPARb/d is expressed ubiquitously in virtually all tissues
and earlier during foetal development. PPARb/d mRNA is
present ubiquitously, with a higher expression in the
digestive tract and placenta [19–21]. In the CNS PPARb/d
is preferentially found in the cerebellum, brain stem and
cortex, was enriched in the dentate gyrus/CA1 region and
was found in immature oligodendrocytes. Its activation
promotes differentiation, myelin maturation and turnover
[22, 23]. PPARc receptors are distributed in several cell
types and tissues. Given the role of PPARc in regulating
glucose and lipid metabolism, in promoting lipid storage
and adipocyte differentiation [24–26], PPARc is expressed
in white and brown adipose tissue and in the CNS during
foetal development of rodents. PPARc is abundantly
expressed in white adipose tissue, and is present at lower
levels in skeletal muscle, heart and liver [19–21]. In the
CNS, PPARc is expressed in several cell types including
neurons, astrocytes, oligodendrocytes and microglia [16,
26–28]. In neurons, PPARc immunoreactivity appears
mainly as a nuclear labeling although sometimes cyto-
plasmic staining is detectable in some cortical neuron [28].
High levels of PPARc have been found in the piriform
cortex and olfactory tubercle, in the basal ganglia, in
rhomboid, centromedial, and parafascicular thalamic
nuclei, in the reticular formation, and in the stellate cells of
cerebellar cortex [28]. PPARc is expressed in the basal
ganglia, and in areas expressing dopamine receptors.
PPARc is expressed in adult cultured cortical astrocytes
[27, 28].
PPARc in Models of Parkinson´s Disease
Parkinson’s disease (PD) is a chronic neurodegenerative
disorder characterized by the progressive loss of dopami-
nergic neurons of the substantia nigra pars compacta,
resulting in deficiency of nigrostriatal dopamine transmis-
sion. One pathological feature of the disease is the presence
of Lewy bodies that are intraneuronal proteinaceous cyto-
plasmic inclusions, which include a-synuclein, ubiquitin,
and neurofilaments, and are found in all affected brain
regions. The basic characteristics of PD include tremor,
rigidity, bradykinesia and impaired balance. PD occurs
most commonly as a sporadic form (95 %), while familial
forms make up the remainder, involving mutations in an
array of proteins that include PINK1, PARKIN, LRRK2,
fbxo-7 and DJ-1 [29], although environmental factors such
as chemicals, pesticides and metals may increase the risk of
developing PD [30–32]. Currently there is no effective
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treatment that slows the progression of the disease, and
management remains symptomatic. Although the specific
pathomechanism of PD is still unclear, there is ever
growing evidence suggesting the involvement of mito-
chondrial dysfunction, oxidative stress, protein dysfunc-
tion, apoptosis, autophagy and chronic neuroinflammation.
In recent years, the neuroprotective effects of PPARc
agonists has been assessed in several in vitro and in vivo
models of several neurodegenerative conditions including
PD [33, 34], Alzheimer’s disease [35, 36], cerebral ische-
mia [37] and amyotrophic lateral sclerosis [38]. The
potential mechanisms of neuroprotection by PPARc ago-
nists in PD are summarised in (Fig. 1).
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)
administration has been widely used in animals to selec-
tively target dopaminergic neurons and so reproduce PD
symptoms [39]. In the acute MPTP model in the rodent, the
PPARc agonist pioglitazone blocked dopaminergic neuro-
degeneration and reduced astrocytic and microglial acti-
vation. However, pioglitazone treatment did not alleviate
MPTP-induced loss of tyrosine hydroxylase in the striatum
and had only partially protective effects on the MPTP-
induced decline in striatal tissue levels of dopamine [40].
In another study pioglitazone was shown to protect against
chronic MPTP-induced neurotoxicity, with reduced acti-
vation of microglia, reduced induction of iNOS-positive
cells and fewer glial fibrillary acidic protein (GFAP)
positive cells in both striatum and substantia nigra [41].
Recently it has also been shown that pioglitazone protected
against MPTP induced neurotoxicity by the inhibition of
monoamine oxidase-B in the striatum. Therefore, blocking
the conversion of MPTP to its active toxic metabolite
MPP?, via inhibition of monoamine oxidase-B [42].
Treatment with rosiglitazone in the chronic MPTP (plus
probenecid) mouse model, completely prevented motor and
olfactory dysfunction and loss of dopaminergic neurons in
the substantia nigra. Rosiglitazone partially protected
against loss of striatal dopamine, whereas decreases in
DOPAC and dynorphin mRNA in the striatum were com-
pletely abolished. Also astrogliosis and number of acti-
vated microglia were reduced as assessed by GFAP and
CD11b immunostaining, respectively, without affecting
MPTP metabolism [43]. In the same model of MPTP plus
probenecid, treatment with rosiglitazone was also effective
in protecting against partial degeneration of the substantia
nigra and the decline of striatal dopamine [33]. In a recent
study, pioglitazone was also neuroprotective and antiin-
flammatory in an MPTP model in the rhesus monkey, with
a significant improvement in a clinical rating score.
Behavioral recovery was associated with preservation of
nigrostriatal dopaminergic markers and reduced infiltration
by CD68-positive macrophages in the nigrostriatal area
[44]. More recently, the administration of a non-TZD
partial PPARc agonist, was again shown to be neuropro-
tective in MPTP-induced neurodegeneration, associated
with downregulation of neuroinflammation, decreased
oxidative stress, and modulation of PPARc and PPARc
coativator-1a (PGC-1a) expression [45].
Intrastriatal injection of lipopolysaccharide (LPS) in rats
has also served to model degeneration of dopaminergic
neurons in PD. In this model pioglitazone prevented the
loss of dopaminergic neurons and the decline in striatal
dopamine levels. Pioglitazone normalized COX-2 expres-
sion and increased the expression of uncoupling protein 2
(Uncoupling protein 2 is one of five acknowledged
uncoupling proteins and it is located in the inner mito-
chondrial membrane, where it helps reduce the proton
gradient. Also, uncoupling protein 2 may be involved in
PD) and increased the expression of mitoNEET, while
iNOS induction and oxidative stress were reduced [46, 47].
In dopaminergic neuron-glial cultures, pioglitazone pro-
tected neurons from LPS by inhibiting abnormal microglial
activation, interfering with phosphorylation of Jun N-ter-
minal kinase and nuclear factor kappa-B, and by sup-
pressing cyclooxygenase-2 expression and the subsequent
prostaglandin E(2) synthesis [48]. Pioglitazone also pro-
tected dopaminergic neurons against LPS damage by
inhibiting iNOS expression and nitric oxide generation by
differential regulation of p38 mitogen-activated protein
kinase and the phosphoinositide 3-kinase/protein kinase B
pathway [49]. Microglial activation has been implicated in
the pathogenesis of PD and is believed to aggravate neu-
ronal injury [33, 50]. The anti-inflammatory actions of
rosiglitazone against LPS were mediated by its ability to
increase IL-4 expression [51]. Thus, production of pro-
inflammatory cytokines has been described in a 6-hy-
droxydopamine (6-OHDA) model of PD, where microglial
activation was observed [52]. A recent study demonstrated
that pioglitazone did not exert any protection in the
6-OHDA model. The lack of effect of pioglitazone in this
model was attributed to the severity of the damage caused
by 6-OHDA. However, pioglitazone protected against
neuronal loss and motor behaviour in the acute MPTP
model [53]. In the 6-OHDA-lesioned rat, the activation of
PPARc receptors by rosiglitazone significantly attenuated
the production of both COX-2 and TNF-a expression and
increased GFAP expression in the striatum [54].
It has been demonstrated that PPARc has actions on
mitochondrial function. PPARc activation increased mito-
chondrial membrane potential and protected cells from
apoptosis following growth factor withdrawal [55]. Piog-
litazone also increased neuronal glucose uptake and
restored brain ATP levels [56, 57]. Pioglitazone increased
mitochondrial DNA content, oxygen consumption, PGC-
1a and mitochondrial transcription factor A (TFAM) in
human adipose tissue and in the neuronal-NT2 cell line
310 Neurochem Res (2015) 40:308–316
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Fig. 1 Pathways involved in neuroprotection by PPARc and PGC-1a in
PD. Mitochondrial dysfunction, oxidative stress, proteosomal dysfunc-
tion, neuroinflammation, autophagy and apoptosis are all implicated in the
pathogenesis of PD. Environmental factors and toxins (rotenone, MPTP,
MPP? and 6-OHDA) directly induce both oxidative stress and mitochon-
drial dysfunction. Different toxins increase oxidative stress (ROS) and
cause mitochondrial dysfunction, both increase [Ca2?], decrease ATP,
decrease mitochondrial membrane potential, decrease oxygen consump-
tion and cause failure in autophagy, proteosomal dysfunction and
abnormal protein aggregation which ultimately lead to neuronal death.
Activated microglia release inflammatory cytokines and increase ROS,
driving neuronal degeneration. DJ-1 and PARKIN mutations cause
aggregation of a-synuclein and PARKIN/PINK-1 mutations cause failure
in autophagy. Mutations in the PARKIN gene cause protein misfolding.
Mutations in PARKIN also increase expression of the PARIS, thereby
repressing the expression of PGC-1a. PPARc agonists inhibit microglial
activation and reduce inflammation by decreasing expression of cytokines,
TNF-a, COX2 and iNOS. PPARc agonists reduced apoptosis by
inhibition of BAX, IL2, IL1b and by increasing Bcl-2 expression. PPARc
agonists increase antioxidant defences, mitochondrial biogenesis, oxygen
consumption, mitochondrial membrane potential, autophagy, PGC-1a
and other transcription factors. Moreover, PGC-1a induces the expression
of downstream target genes involved in mitochondrial biogenesis,
transcription factors and antioxidant defences. Thus, PGC-1a and PPARc
agonists regulate the expression of several target genes involved in
neuronal survival and neuroprotection by inhibiting mitochondrial
dysfunction, oxidative stress, proteosomal dysfunction, autophagy, neur-
oinflammation and apoptosis
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[58–61]. Rosiglitazone induced both mitochondrial bio-
genesis and glucose utilization in mouse brain [62]. In
addition, Pioglitazone stabilizes MitoNEET, an iron-sulfur
containing outer mitochondrial membrane protein which
regulates oxidative capacity [63–65].
Rotenone is a complex I inhibitor and has been widely
used to model PD [39, 66]. Consequently, pioglitazone
protected against the reduction of locomotor activity and
decline in striatal dopamine levels induced by rotenone
[67]. In a recent study, it was found that rotenone irre-
versibly decreased mitochondrial mass, membrane poten-
tial and oxygen consumption, while increasing free radical
generation and autophagy in human differentiated SH-
SY5Y cells. Similar changes were seen in PINK1 knock-
down cells, in which the membrane potential, oxygen
consumption and mitochondrial mass were all decreased.
In both models, all these changes were reversed by treat-
ment with rosiglitazone, which increased mitochondrial
biogenesis, increased oxygen consumption and suppressed
free radical generation and autophagy [68]. Rosiglitazone
significantly increased the expression of proteins related
with antioxidant defences and mitochondrial biogenesis
(SOD1, Nuclear factor (erythroid-derived 2)-like 2 (Nrf2),
NAD(P)H:quinone oxidoreductase 1 (NQO1), PGC-1 and
TFAM). Thus, rosiglitazone was neuroprotective in two
different models of mitochondrial dysfunction associated
with PD through a direct impact on mitochondrial function
[68]. Nrf2 is a pivotal upstream transcription factor
responsible for the regulation of redox balance. Nrf2 is
normally sequestered in the cytoplasm by its inhibitor
Keap1. In response to oxidative stress, Nrf2 translocates to
the nucleus and dimerizes with another member of the
Cap’n’Collar/basic leucine zipper family of transcription
factors [69], activating transcription by binding to an
antioxidant response element (ARE) located in the pro-
moter of a number of antioxidant genes, including NQO1,
Heme oxygenase-1 (HO-1) and Glutathione S-transferase
[70, 71]. A number of studies have suggested that Nrf2 and
NQO1 protect against cellular dysfunction in different
models of PD [72–74]. Recently, it was demonstrated that
rosiglitazone increased expression of Nrf2 and the antiox-
idant enzyme HO-1 acting through the PPARc-pathway,
enhancing elimination of ROS in hepatocytes [75]. The
protective effects of TZDs have been attributed also to their
antioxidant and anti-apoptotic properties. For that reason,
rosiglitazone was shown to protect human neuroblastoma
cells against MPP? induced mitochondrial dysfunction by
anti-oxidant properties and anti-apoptotic activity via
inducing expression of SOD and catalase and regulating
the expression of Bcl-2 and Bax and increase the mito-
chondrial membrane potential [76]. In the MPP? model,
rosiglitazone treatment did not alter SOD activity but there
was an increase of glutathione S-transferase activity and
the protective effects of rosiglitazone were not blocked by
the PPARc antagonist GW9662, suggesting that these
effects may be independent of PPARc activation [77].
Acetaldehyde, an inhibitor of mitochondrial function,
causes neuronal death by inducing generation of intracel-
lular reactive oxygen species and cellular apoptosis in
human neuroblastoma cells. Rosiglitazone reversed acet-
aldehyde induced apoptosis by inducing the expression of
anti-oxidant enzymes such as SOD and catalase and by
regulating expression of Bcl-2 and Bax [78].
The PPARc Coativator-1a (PGC-1a)
PPARc coactivator-1a (PGC-1a) was discovered in brown
adipose tissue as a PPARc coactivator during the ther-
mogenic response to cold [79]. Two other coactivators
have been identified, PGC-1b and PGC-1-related coacti-
vator. PGC-1a and PGC-1b display a great degree of
homology but are slightly differently regulated [80]. PGC-
1a can regulate other nuclear receptors such as the thyroid
hormone receptor, the oestrogen receptor, and the oestro-
gen-related receptor a, aside of acting as a coactivator for
PPARs [81]. On the other hand, PGC-1a acts also as a
coactivator for other transcription factors such as the
nuclear respiratory factors 1 and 2 (NRF-1 and 2), TFAM,
myocyte enhancer factor 2, FOXO receptors and hepatic
nuclear factor 4 [81]. PGC-1a is highly expressed in tis-
sues with a high-energy demand, such as brown adipose
tissue, brain, heart, liver, pancreas, skeletal muscle and
kidney [82]. It plays a central role in driving and coordi-
nating mitochondrial biogenesis and respiration, gluco-
neogenesis and glucose transport, glycogenolysis, fatty
acid oxidation, peroxisomal remodeling, muscle fiber-type
switching, oxidative phosphorylation and is preferentially
expressed in muscle enriched for type I myocytes and can
convert the type II myocytes to type I fibers [83]. In
addition, PGC-1a also regulates the expression of several
ROS detoxifying enzymes, such as SOD1 and 2, catalase
and glutathione peroxidase-1 [84]. The activity of PGC-1a
is influenced by post-transcriptional modifications, such as
protein phosphorylation, acetylation, sumoylation, and
methylation [81, 85, 86]. PGC-1a expression can be
induced by cold exposure, fasting, and exercise, which
require energy expenditure [79, 83, 87]. It has been
reported that PGC-1a expression is decreased with aging,
possibly owing to decreased sirtuin1 (SIRT1) levels [85]
or by the action of p53 that is activated by telomere
shortening and suppresses PGC-1a [88]. Drugs such as
resveratrol, can act by decreasing PGC-1a acetylation,
producing a subsequent increase in PGC-1a activity and
its downstream genes [89].
312 Neurochem Res (2015) 40:308–316
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PGC-1a in PD
The role PGC-1a, which is involved in mitochondrial
biogenesis and respiration, has been implicated in PD. As
mentioned above, PGC-1a induces the expression of
ROS scavenging enzymes (glutathione peroxidase-1,
catalase and SOD) and reduces oxidative stress [84]. An
increased vulnerability to MPTP induced degeneration of
nigral dopaminergic neurons was observed in PGC-1a
knockout mice, suggesting a critical role of PGC-1a in
neuroprotection. Therefore, Increasing PGC-1a levels
dramatically protected neural cells from oxidative stress
and cell death [84]. These studies suggested compelling
evidence for a role of PGC-1a in neurodegenerative
diseases and as a good candidate for the treatment of PD.
The mechanisms of neuroprotection by PGC-1a in PD
are shown in (Fig. 1).
Activation of PGC-1a increased the expression of
nuclear-encoded subunits of the mitochondrial respiratory
chain and prevented the dopaminergic neuron loss
induced by mutant a-synuclein or the pesticide rotenone
in cellular disease models [90]. Also, it has been shown
that PGC-1a knockdown increased a-synuclein accumu-
lation and led to down regulation of the AKT/GSK-3b
signaling pathway in human neuronal cells [91]. A sub-
strate for PARKIN, the PARKIN-interacting substrate
(PARIS), is a zinc-finger protein which is highly
expressed in the substantia nigra. PARIS represses the
expression of PGC-1a and NRF-1 and the site of inter-
action between PARIS and PGC-1a is a sequence that is
involved in the regulation of insulin responsiveness and
energy metabolism. Conditional knockout of PARKIN in
adult animals led to progressive loss of dopamine neu-
rons which was dependent on PARIS expression. More-
over, overexpression of PARIS led to the selective loss
of dopamine neurons in the substantia nigra, and this was
reversed by either PARKIN or PGC-1a coexpression
[92]. A recent study reported that PINK1 mutations
impair PARKIN recruitment to mitochondria in neurons,
increased mitochondrial copy number, and upregulation
of PGC-1a [93]. Other studies, have shown that trans-
genic overexpression of PGC-1a or activation of PGC-1a
by resveratrol protect dopaminergic neurons in the MPTP
mouse model of PD [94]. Recently it was shown that
adenoviral delivery of PGC-1a in the nigrostriatal system
increased dopaminergic death [95]. This effect could be
the result of excessive overexpression of PGC-1a,
resulting in mitochondrial hyperactivity and increased
production of ROS. Apparently, the studies related to the
role of PGC-1a in PD have provided inconsistent data
regarding the effects of PGC-1a activation or overex-
pression in PD [96].
Conclusion
In conclusion, a number of molecular pathways including
oxidative stress, mitochondrial dysfunction, protein dys-
function, apoptosis, autophagy and neuroinflammation are
implicated in the pathophysiology of PD. As currently
available drugs cannot slow down the progression of the
disease, using a combination of several pharmacological
agents may offer better promise for neuroprotection,
modulating several molecular pathways involved in the
pathophysiology simultaneously. PPARc agonists and
PGC-1a exhibit a wide range of activities that positively
influence the pathology of PD in experimental models, and
they have the capacity to be neuroprotective by regulating
the expression of genes involved in neuronal survival
processes. The compelling results from in vitro and in vivo
models of PD underline the beneficial effects of PPARc
agonists and PGC-1a for future therapies. Thus, PPARc
agonists and PGC-1a could be valuable potential thera-
peutic targets for neurodegenerative diseases. Finally,
understanding the molecular mechanisms by which
PPARc and PGC-1a exert their neuroprotective effects
will be helpful in developing an effective treatment for
PD.
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